Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Background: The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies …

Importance Women may respond differently to certain treatments for heart failure (HF) with
reduced ejection fraction (HFrEF) than men. Objective To investigate the efficacy and safety …

Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or
worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Importance In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved
Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first …

Importance Dapagliflozin was recently shown to reduce cardiovascular death or worsening
heart failure (HF) events in patients with HF with mildly reduced or preserved ejection …

Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in
Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk …

Aims Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular
death among patients with heart failure with mildly reduced or preserved ejection fraction. In …